康力欣胶囊联合甘露聚糖肽治疗肝癌的临床研究  

Clinical study on Kanglixin Capsules combined with mannatide in treatment of liver cancer

作　　者：王四明[1] 

机构地区：[1]玉溪市人民医院肿瘤科,云南玉溪653100

出　　处：《现代药物与临床》2016年第6期859-862,共4页Drugs & Clinic

摘　　要：目的探讨康力欣胶囊联合甘露聚糖肽治疗肝癌的临床疗效。方法选取2014年2月—2015年7月在玉溪市人民医院肿瘤科接受治疗的肝癌患者86例,分成对照组(43例)和治疗组(43例)。所有患者均给予必要的化疗和碘油栓塞治疗,1次/周,连续治疗2周。对照组在此基础上静脉滴注甘露聚糖肽注射液,10 mg加入250 mL生理盐水,1次/d。治疗组在对照组基础上口服康力欣胶囊,3粒/次,3次/d。两组患者均连续治疗4周。观察两组的临床疗效,同时比较两组生存质量、免疫功能和血清基质金属蛋白酶水平改善情况。结果治疗后,对照组客观缓解率(ORR)为41.86%,临床获益率(CBR)为74.42%;治疗组ORR为65.12%,CBR为90.70%,两组ORR、CBR比较差异具有统计学意义(P<0.05)。治疗后,对照组与治疗组患者生存质量改善率分别为74.42%和93.02%,两组差异比较具有统计学意义(P<0.05)。治疗后,两组CD^(3+)、CD^(4+)和CD^(4+)/CD^(8+)上升,差异有统计学意义(P<0.05);且治疗组变化的更显著(P<0.05)。治疗后,两组血清基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)水平均较同组治疗前明显降低(P<0.05);与对照组相比,治疗组降低的更显著(P<0.05)。结论康力欣胶囊联合甘露聚糖肽治疗肝细胞癌具有很好的临床疗效,可以提高患者免疫能力及改善生活质量,具有一定的临床应用推广价值。Objective To investigate the clinical efficacies of Kanglixin Capsules combined with mannatide in treatment of liver cancer. Methods Patients（86 cases） with liver cancer from February 2014 to July 2015 in People＇s Hospital of Yuxi City were divided into control group（43 cases） and treatment group（43 cases）. All patients were given necessary chemotherapy and lipiodol embolization therapy, once a week, and were treated for 2 weeks. Based on the foresaid, the patients in the control group were iv administered with Mannatide Injection, 10 mg added into normal saline 250 mL, once daily. The patients in the treatment group were po administered with Kanglixin Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of survival quality, immune function and serum matrix metalloproteinase levels in two groups were compared. Results After treatment, ORR and CBR in the control group were 41.86% and 74.42%, respectively, accordingly, 65.12% and 90.70% in the treatment group, and there were differences between two groups（P〈 0.05）. After treatment, improvement rate of survival quality in the control and treatment group were 74.42% and 93.02%, respectively, and the difference was statistically significant（P〈 0.05）. After treatment, CD^（3＋）, CD^（4＋）, and CD^（4＋）/CD^（8＋） were increased（P〈 0.05）; And the changes of immune function in treatment were more significant than those in control group（P〈 0.05）. After treatment, the serum MMP-2 and MMP-9 levels decreased more significantly than those before treatment（P〈 0.05）. But the reduction in treatment group was more significant than those in the control group（P〈 0.05）. Conclusion Kanglixin Capsules combined with Mannatide Injection has a good clinical efficacy in the treatment of hepatocellular carcinoma, and can improve the immune function and survival quality, which

关 键 词：康力欣胶囊 甘露聚糖肽注射液 肝细胞癌 临床疗效 

分 类 号：R979.1[医药卫生—药品]